8-K: Xtant Medical Completes $19.2M Strategic Asset Divestiture

Xtant Medical Holdings, Inc. completed the sale of its Coflex and CoFix products and its international Paradigm Spine business for an initial $19.2 million, reducing debt and sharpening strategic focus.

Summary

• Xtant Medical Holdings, Inc. (XTNT) completed the sale of its Coflex and CoFix products and its international Paradigm Spine GmbH business to Companion Spine, LLC and its affiliates on December 1, 2025.
• The total initial purchase price for the divestitures was approximately $19.2 million, comprising $11.0 million in cash and an $8.2 million unsecured promissory note.
• The Coflex/CoFix Divestiture had a total purchase price of $17.5 million, with $7.5 million previously paid as non-refundable deposits, $1.8 million paid in cash at closing, and an $8.2 million unsecured promissory note issued by Companion Spine.
• The Paradigm Divestiture had an initial purchase price of $1.7 million, paid in cash at closing.
• An additional $1,742,000.00 increase to the Paradigm Purchase Price, resulting from estimated net working capital exceeding target and estimated closing date cash, is due by January 15, 2026.
• Approximately $8.0 million of the net cash proceeds from the divestitures was used to prepay a portion of the company's term loan with MidCap Financial Trust, reducing the outstanding balance to $14.4 million.
• An additional $1.6 million will be required to be prepaid on the term loan if and when the Companion Spine Note is repaid.
• The company expects to enhance its focus on its core biologics business, drive innovation, and deliver sustained improvements in financial performance.
• Pro forma financial information indicates an estimated net gain on sale of $3.9 million from the divestitures.
• Pro forma net income for the nine months ended September 30, 2025, increased by $1.855 million, and net loss for the twelve months ended December 31, 2024, improved by $4.163 million, giving effect to the divestitures.

Sentiment

Score: 7

Explanation: The filing indicates a positive strategic move for Xtant Medical, characterized by significant debt reduction, increased liquidity, and a sharpened focus on its core biologics business. Management's expectation to avoid future external capital raises is a strong positive. While the divestiture removes revenue, the overall financial and strategic repositioning is favorable, though the long-term impact on the core business's growth needs to be observed.

Positives

• Significant reduction in long-term debt by approximately $8.0 million, improving the company's financial leverage.
• Increased cash liquidity from the transaction proceeds, with $11.0 million in cash received initially.
• Strategic refocusing on the core biologics business, which management expects to drive innovation and sustained financial performance.
• Management anticipates operating without the need for additional external capital due to the transaction proceeds and anticipated cash flows from operations.
• Pro forma analysis shows an estimated net gain on sale of $3.9 million and an improvement in net income/loss for prior periods.

Negatives

• The divestiture removes revenue streams and associated market presence from the Coflex/CoFix products and the international Paradigm Spine business.
• An $8.2 million unsecured promissory note introduces credit risk, although it is short-term, maturing on January 15, 2026.
• Future purchase price adjustments for Coflex/CoFix (inventory valuation) and Paradigm (cash, indebtedness, net working capital) could potentially reduce the final proceeds or require cash payments from Xtant.

Risks

• The anticipated benefits of the transactions, such as enhanced focus and sustained financial performance, may not be realized as expected or at all.
• Exposure to potential litigation and adverse tax consequences related to the divestitures.
• The company's ability to service its remaining debt, comply with debt covenants, and access additional indebtedness if needed.
• The ability to maintain sufficient liquidity to fund operations without additional external financing, and to obtain financing on favorable terms if required.
• The actual net gain on the divestitures may differ materially from the current estimate of $3.9 million.

Future Outlook

The company intends to use the net proceeds from the transactions to reduce long-term debt and provide additional cash liquidity. Management expects to enhance its focus on the core biologics business, driving innovation for surgeons and patients, and delivering sustained improvements in financial performance. The company anticipates that these actions, combined with expected cash flows from operations, will enable it to continue operating without the need for additional external capital.

Management Comments

• Sean Browne, President and CEO of Xtant Medical, stated: 'The sale of these businesses to Companion Spine represents a significant step forward for Xtant as we enhance our focus on our core biologics business, driving innovation for surgeons and patients, and delivering sustained improvements in our financial performance.'
• Sean Browne also noted: 'Importantly, we expect that the net proceeds from this transaction, together with our anticipated cash flows generated from operations, will enable us to continue operating without the need for additional external capital. We are immensely proud to have reached this inflection point.'

Industry Context

This strategic divestiture aligns with a broader industry trend where medical technology companies streamline their portfolios to focus on core competencies and higher-growth segments. By shedding non-core assets like Coflex/CoFix and the international hardware business, Xtant Medical aims to concentrate resources on its orthobiologics business, potentially improving operational efficiency and market competitiveness within that specialized niche. This move could allow Xtant to better compete with companies solely focused on biologics by allocating capital and R&D more effectively.

Comparison to Industry Standards

• Not explicitly detailed in the filing. The divestiture represents a strategic realignment rather than a direct performance comparison against industry benchmarks or specific competitor transactions.

Stakeholder Impact

• Shareholders: Expected to benefit from improved financial health, reduced debt, increased liquidity, and a clearer strategic focus on the core biologics business, potentially leading to sustained financial performance.
• Employees: Employees associated with the divested Coflex/CoFix products and Paradigm OUS business are now part of Companion Spine, LLC or its affiliates.
• Customers: Customers of the divested products and OUS business will now be served by Companion Spine, LLC or its affiliates.
• Creditors (MidCap Financial Trust): The company has prepaid $8.0 million of its term loan, reducing its outstanding debt obligation and improving its credit profile.

Next Steps

• Companion Spine to pay the $8.2 million unsecured promissory note to Xtant Medical on or before January 15, 2026.
• Companion Spine to pay the $1,742,000.00 Estimated Purchase Price Increase for Paradigm to Xtant Medical on or before January 15, 2026.
• The parties to promptly, and no later than December 12, 2025, deliver a duly notarized deed evidencing the transfer of Paradigm shares.

Key Dates

Recommendation

The divestiture is a strategically sound move, reducing debt and allowing Xtant Medical to focus on its core biologics business. This repositioning is generally positive for long-term value creation. However, a 'hold' recommendation is appropriate for a seasoned investor as the market will need time to assess the execution of the new strategy and the performance of the streamlined core business before a stronger 'buy' recommendation can be made. The immediate impact is positive, but future growth and profitability from the focused operations are key determinants for a more aggressive stance.

Keywords

Xtant Medical, XTNT, Divestiture, Asset Sale, Coflex, Paradigm Spine, Medical Technology, Spinal Implants, Orthobiologics, Debt Reduction, SEC Filing, 8-K, Companion Spine